Share on StockTwits

Ocera Therapeutics (NASDAQ:OCRX) CFO Sharon Tetlow acquired 3,000 shares of Ocera Therapeutics stock on the open market in a transaction dated Friday, July 11th. The shares were purchased at an average cost of $5.83 per share, for a total transaction of $17,490.00. Following the purchase, the chief financial officer now directly owns 3,000 shares of the company’s stock, valued at approximately $17,490. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Ocera Therapeutics (NASDAQ:OCRX) opened at 6.00 on Thursday. Ocera Therapeutics has a 1-year low of $5.73 and a 1-year high of $19.94. The stock has a 50-day moving average of $7.07 and a 200-day moving average of $10.75. The company’s market cap is $93.2 million.

Ocera Therapeutics (NASDAQ:OCRX) last announced its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.43) by $0.16. On average, analysts predict that Ocera Therapeutics will post $-1.89 earnings per share for the current fiscal year.

Separately, analysts at JMP Securities initiated coverage on shares of Ocera Therapeutics in a research note on Wednesday, June 11th. They set an “outperform” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $18.40.

Ocera Therapeutics, Inc, formerly Tranzyme, Inc, is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (NASDAQ:OCRX) motility disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.